

Department of Health Therapeutic Goods Administration

SERIOUS SHORTAGE SUBSTITUTION NOTICE

Notice Reference Number	SSSN 20-05
-------------------------	------------

This Notice applies for the following dates

From	4/09/2020	То	31/12/2020
------	-----------	----	------------

This Notice applies only to the following medicines

Name of medicine in shortage (including strength and formulation):	Prazosin (as hydrochloride) tablet blister pack – multiple strengths	
Schedule:	S4: Prescription Only Medicine	
Duration of shortage:	Expected to be resolved between September and December 2020.	
	For further and any updated information, see:	
	https://apps.tga.gov.au/Prod/msi/Search/Details/prazosin-hydrochloride	

Details of medicines to be supplied under this SSSN

Name of medicines (including strength and formulation) to be supplied	Prazosin (as hydrochloride) tablet blister pack – alternative strength(s)
Same formulation but different strength?	Yes, see dosage substitution table below

PO Box 100 Woden ACT 2606 ABN 40 939 406 804
Phone: 1800 020 653 or 02 6232 8644 Fax: 02 6232 8112
Email: info@tga.gov.au https://www.tga.gov.au



Same active but different salt?	No
Different dose form?	No

Dosage substitution table

Original medicine dose (single dose)	1 mg	2 mg	5 mg
Alternative strength to be supplied as a	2 mg	1 mg	1 mg and/or 2 mg
substitute	Ensure correct dose is provided – Follow dosage substitution regimen below		
Dosage substitution regimen	Calculate the number of tablets required to provide the prescribed dose, noting that tablets may need to be cut in half. Dose interval remains unchanged		
Any restrictions on this dose form (e.g. dose intervals)	N/A		
Any limitations on substitution	Consideration must be given to the appropriateness of the number of tablets needed to replace the original dose		

Conditions:

- Total quantity supplied under this protocol must be equivalent to the number of days supplied on original prescription.
- The patient/carer must provide a valid prescription for the original medicine that is in shortage.
- The patient/carer must consent to receiving a substitute medicine supplied pursuant to the notice.
- The pharmacist may, in their professional judgement, determine that the patient is not suitable to receive alternative medicine under the notice e.g. known previous hypersensitivity or severe adverse reaction to excipients.